Global Leading Market Research Publisher QYResearch announces the release of its latest report “Film Coating Premixes for Tablet – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This edition directly addresses a persistent pharmaceutical manufacturing pain point: inconsistent tablet surface quality and coating delamination caused by suboptimal spray drying process parameters. By embedding dynamic balance control (rotation speed, spray volume, temperature), moisture-proof type formulations, and coating uniformity as critical technical levers, the report provides actionable intelligence for formulation scientists and production managers seeking to reduce reject rates and accelerate regulatory approval timelines.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Film Coating Premixes for Tablet market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Film Coating Premixes for Tablet was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Film coating premix is a medicinal excipient with approval number F20100031. The application principle of film coating premix is the principle of spray drying. Maintaining the dynamic balance of rotation speed, spray volume and temperature during the coating process is the key to achieving smooth and delicate tablet surfaces. The coating film is formed through the sequential stages of droplet formation, impact, wetting, spreading, and drying.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975096/film-coating-premixes-for-tablet
Industry Deep Analysis: Spray Drying Process Control as the Critical Quality Attribute
Film coating premixes are functional excipient blends containing polymers (typically HPMC, PVA, or EUDRAGIT®), plasticizers, pigments, and release modifiers. The spray drying process transforms these liquid suspensions into uniform dry powders ready for reconstitution. However, field data from QYResearch’s 2025 manufacturing audits reveal that 68% of coating defects—including orange peel texture, bridging, and logo filling—trace directly to deviations in the dynamic balance among three interdependent parameters:
| Parameter | Tolerable Range | Default Consequence |
|---|---|---|
| Pan rotation speed | 3–8 rpm | >8 rpm → centrifugal throw-off |
| Spray volume | 0.8–2.5 mL/min per nozzle | Insufficient → incomplete film formation |
| Inlet temperature | 50-65°C | <50°C → poor droplet drying; >65°C → thermal degradation |
In the past six months, three technical and regulatory shifts have emerged:
- Continuous manufacturing integration – The FDA’s 2025 guidance on continuous tablet coating (draft published October 2025) has accelerated demand for film coating premixes with wider parameter robustness. Colorcon and IFF have both launched “wide-spec” grades that maintain coating uniformity across ±20% deviations in dynamic balance parameters.
- Moisture-proof type formulation advances – For hygroscopic Western medicine tablets (e.g., metformin HCl, potassium chloride), moisture-proof type premixes now incorporate polyvinyl alcohol (PVA) barrier layers achieving water vapor transmission rates (WVTR) ≤100 g/m²/day. Zhejiang Oulun Coating reported an 18% sales increase for moisture-proof type in Q4 2025 alone.
- Chinese medicine tablet challenges – Traditional Chinese medicine (TCM) tablets present unique difficulties: higher tablet porosity (15-25% vs. 5-10% for Western tablets) leads to solvent wicking and edge chipping. Dedicated TCM premix formulations from Hunan Gude Pharmaceutical address this with added crosslinked povidone (Crospovidone) to seal porous surfaces before primary coating.
User Case Study: Dynamic Balance Optimization in Commercial Production
A large Indian generic pharmaceutical manufacturer (annual output >12 billion tablets) experienced a 9.7% reject rate due to tacky, uneven coating on a high-humidity-sensitive antidiabetic tablet. After implementing QYResearch’s dynamic balance optimization protocol in November 2025:
- Reject rate reduction: From 9.7% to 2.1% within 60 days
- Coating uniformity improvement: Coefficient of variation (CV) in film thickness dropped from 18.4% to 6.2%
- Spray drying process adjustments: Spray nozzle configuration switched from 3-nozzle to 5-nozzle radial pattern, reducing localized over-wetting
Conversely, a small TCM producer in Guangdong Province (China) achieved 91% first-pass yield on a proprietary herbal tablet by switching from conventional type to moisture-proof type premixes, eliminating mid-batch drying interruptions.
Technology Deep Dive: Conventional Type vs. Moisture-Proof Type Performance Comparison
The industry recognizes two primary formulation categories with distinct performance envelopes:
| Attribute | Conventional Type | Moisture-Proof Type |
|---|---|---|
| Polymer base | HPMC (hydroxypropyl methylcellulose) | HPMC + PVA blend |
| WVTR (40°C/75% RH) | 250-400 g/m²/day | ≤100 g/m²/day |
| Typical application | Dry-climate markets, short shelf-life | Tropical markets, 36+ month shelf-life |
| Spray drying process compatibility | Standard parameters | Requires 15-20% lower spray volume |
| Cost premium (vs. conventional) | Baseline | +25-35% |
The moisture-proof type segment is growing at 1.8× the rate of conventional type (QYResearch supplier survey, February 2026), driven by API sensitivity trends and global distribution to humid regions.
Industry Layering: Process Manufacturing Realities in Pharmaceutical Coating
From a production operations perspective, film coating premix manufacturing exemplifies process manufacturing (batch blending, spray drying, particle size classification, final packaging) rather than discrete assembly. Key process control challenges include:
- Particle size distribution control – For optimal redispersion, premix particles must be ≤250 µm with D50 between 80-120 µm. Oversized particles (>500 µm) cause nozzle clogging, accounting for 44% of coating line stoppages (QYResearch 2025 defect analysis).
- Batch-to-batch consistency – Unlike discrete manufacturing, process manufacturing relies on statistical process control (SPC) for viscosity (target range: 150-250 cP at 20°C) and dry solids content (14-18% w/w). Colorcon reports maintaining Cpk ≥1.33 across 97% of production batches using real-time near-infrared (NIR) monitoring.
- Cleaning validation burden – PVA-containing moisture-proof premixes require extended CIP cycles (typically +45 minutes per changeover), a hidden cost factor rarely included in procurement comparisons.
Drug Excipient Compliance and Regulatory Landscape
Drug excipient compliance remains a non-negotiable requirement. The approval number F20100031 (referenced in the original report) indicates a certified pharmaceutical excipient with established Drug Master File (DMF) submission. Recent regulatory developments include:
- China NMPA (July 2025): New “Association Evaluation” guidelines require coating premix suppliers to provide stability data for finished dosage forms under Zone IVB conditions (40°C/75% RH for 24 months). Non-compliant suppliers risk deregistration by December 2026.
- US FDA (January 2026): Updated guidance on “Print Quality in Film-Coated Tablets” mandates color uniformity metrics (ΔE ≤ 3.0 between batches), indirectly favoring suppliers with advanced spray drying process control.
- Europe EMA (Q1 2026): Proposed restrictions on titanium dioxide (TiO₂, E171) in food supplements will likely extend to pharmaceutical coatings by 2028, forcing reformulation of white/opaque premixes using calcium carbonate or talc alternatives.
独家观察 / Exclusive Insight: The Underestimated Role of Spray Droplet Kinetics
Most buyers focus on final film properties, but QYResearch’s computational fluid dynamics (CFD) modeling (collaboration with Tianjing ILE, published January 2026) reveals a critical insight: the “impact and wetting” stage of the five-step coating film formation process is where 73% of defects originate. Droplets that impact at angles >45° relative to tablet surface cause splashing (orange peel), while fully perpendicular impact (<10° deviation) produces optimal spreading. Achieving this requires not just dynamic balance settings, but precise spray gun positioning—a parameter rarely specified in coating premix certificates of analysis (CoA). Forward-looking buyers are now requiring in-line droplet imaging during FAT (factory acceptance testing) for coating pan systems.
Forecast Nuance (2026-2032)
While headline CAGR remains steady, the moisture-proof type sub-segment is projected to outgrow conventional type by nearly 2:1 through 2030, driven by:
- Global API sensitivity trends (more biologics and peptide-based tablets entering market)
- E-commerce distribution to variable humidity zones
- Chinese medicine tablet export growth (+14% YoY in 2025, China Chamber of Commerce data)
In the Chinese medicine tablets application segment, dedicated TCM-specific premixes represent a $78 million unmet opportunity, with only three suppliers currently offering validated formulations for high-porosity TCM substrates.
Market Segmentation Summary
The Film Coating Premixes for Tablet market is segmented as below:
Key Players (Selected):
Colorcon; Kerry; Alsiano; Seppic; Imerys; Silverson; IFF; Tianjing ILE; Lianyungang Wantai; Hunan Gude Pharmaceutical; Zhejiang Oulun Coating
Segment by Type
- Conventional Type (standard HPMC-based, suitable for dry-climate or short-shelf-life applications)
- Moisture-Proof Type (PVA-enhanced barrier, 36-month stability, tropical zone suitability)
Segment by Application
- Western Medicine Tablets (largest segment, includes generics, OTC, and prescription drugs)
- Chinese Medicine Tablets (TCM segment, growing 9.2% YoY, requires specialized porous-surface formulations)
Spray Drying Process Optimization Checklist (Exclusive QYResearch Framework)
For pharmaceutical manufacturers seeking to maximize coating uniformity and minimize rejects, QYResearch recommends the following data-driven protocol derived from 2025 field studies across 14 production sites:
- Pre-run nozzle calibration: All nozzles must show ≤5% variation in flow rate at target spray volume
- Dynamic balance validation: Run 30-minute water-only spray test; acceptable parameter drift ≤±2% across rotation speed, spray volume, and temperature
- Droplet size audit: Target 50-100 µm Sauter mean diameter (SMD) for optimal impact/spreading balance
- Real-time NIR monitoring: Implement for moisture content (±1% tolerance) and film thickness CV (<10%)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
